Y mAbs Therapeutics (YMAB)

NASDAQ
14.81
+0.13(+0.89%)
After Hours
14.81
0.00(0.00%)
- Real-time Data
  • Volume:
    572,587
  • Day's Range:
    13.98 - 15.20
  • 52 wk Range:
    6.50 - 39.82

YMAB Overview

Prev. Close
14.68
Day's Range
13.98-15.2
Revenue
40M
Open
15.2
52 wk Range
6.5-39.82
EPS
-2.68
Volume
572,587
Market Cap
647.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
452,953
P/E Ratio
-
Beta
1.3
1-Year Change
-56.86%
Shares Outstanding
43,718,165
Next Earnings Date
Aug 17, 2022
What is your sentiment on Y mAbs Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Y mAbs Therapeutics Company Profile

Y mAbs Therapeutics Company Profile

Employees
125

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • 11/5/20: YMAB closed at $48.70 today. That’s a gain of 21.75% from our buy price of $40. ;-)
    0
    • YMAB. 10/5/20 at 11:10 AM. YMAB remains a good buy at or below $40. Last $40.17
      0
      • 8/10/20: YMAB is a buy under $40. Last: $39.96. Looks good going into the Fall ‘20.
        0
        • What news came out friday 29th, Since this nice jump?
          0
          • Trong buy great news to come
            0